ADVA introduces multi-layer cell site gateway to maximize 5G efficiency
5.9.2019 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its FSP 150-XG118Pro, a cell site gateway device specifically designed to meet the challenges of 5G. Ideal for deployment at radio base stations, the ADVA FSP 150-XG118Pro meets urgent demand for ultra-reliable low-latency communications (URLLC) in 5G mobile networks and supports a smooth transition from 1Gbit/s to 10Gbit/s services. The solution also features a temperature-hardened design and precise synchronization capabilities. What’s more, with its industry-leading demarcation technology and pluggable high-performance server, the FSP 150-XG118Pro enables virtual network functions (VNFs) to be hosted at the edge of the network and gives communication service providers (CSPs) and mobile wholesale operators a risk-free route to network functions virtualization (NFV).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190905005062/en/
The ADVA FSP 150-XG118Pro is the ultimate tool for rapid 5G rollouts over existing LTE infrastructure (Photo: Business Wire)
“Our FSP 150-XG118Pro brings high-capacity demarcation and edge aggregation to the radio base station without exceeding strict requirements for space, power and cost. It really is the ultimate tool for rapid 5G rollouts over existing LTE infrastructure,” said Richard Strike, director, product line management, ADVA. “Our FSP 150-XG118Pro empowers mobile network operators (MNOs) to respond to soaring bandwidth needs with 10Gbit/s bandwidth at the radio base station. They can also cater for new URLLC applications that demand data to be processed right where it’s created. And, as the solution has been built with our Oscilloquartz team of network synchronization specialists, it delivers the accurate and stable timing that’s so crucial for 5G applications.”
The ADVA FSP 150-XG118Pro has been specifically engineered to support a seamless, cost-efficient transition from LTE mobile networks to 5G. With multi-layer demarcation and precise synchronization delivery, the cell site gateway device meets all current mobile network requirements, and its 10Gbit/s capacity enables MNOs to utilize the full 5G spectrum. Its open software-defined networking (SDN) control supports automated network slicing and its pluggable server allows it to be upgraded in-service for edge hosting of VNFs. The ADVA FSP 150-XG118Pro’s capacity and edge hosting capabilities also enable enterprises to unlock the potential of the industrial IoT (IIoT). This makes the solution ideal for a wide range of IIoT business cases that require ultra-low latency and massive machine connectivity.
“This new member of our hugely successful and widely deployed FSP 150 family opens the door to a world of new opportunities. It tears down the entry barriers and provides CSPs and businesses with a risk-free route to all the advantages of virtualization,” commented Ulrich Kohn, director, technical marketing, ADVA. “Featuring our award-winning, field-proven Ensemble Connector NFV hosting software, our FSP 150-XG118Pro enables enterprises to seize the full business potential of the IIoT. It supports big data analytics at the very edge of the network, saving significant bandwidth and improving performance. Now businesses can benefit from our vast experience with migrating centrally hosted network functions to the edge. Our customers can focus on revenue-generating services while we handle complex network integration and testing and ensure superb levels of performance.”
Watch this video for more information on the FSP 150-XG118Pro: http://adva.li/fsp-150-xg118pro-video.
Additional details can also be found in these slides: http://adva.li/fsp-150-xg118pro-slides.
A supporting solution brief can be downloaded here: http://adva.li/connecting-5g-new-radios.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190905005062/en/
Contact information
For ADVA press:
Gareth Spence
t +44 1904 699 358
public-relations@advaoptical.com
For ADVA investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@advaoptical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom